1.
Arch Soc Esp Oftalmol (Engl Ed)
; 99(3): 109-132, 2024 Mar.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37949110
RESUMEN
With the advance of cancer therapy in recent years, the knowledge of the mechanisms involved in this disease has increased, which has meant an increase in the quality of life and survival of patients with tumor pathologies previously considered incurable or refractory to treatment. The number of drugs used has increased exponentially in number, and although the implicit toxicity is lower than that of conventional antineoplastic therapy, they lead to the appearance of new associated adverse effects that the ophthalmologist must recognize and manage.